Exelixis, Inc. (EXEL) VP Patrick J. Haley Sells 959 Shares

Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 959 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $23.13, for a total transaction of $22,181.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Patrick J. Haley also recently made the following trade(s):

  • On Monday, February 25th, Patrick J. Haley sold 4,272 shares of Exelixis stock. The shares were sold at an average price of $22.27, for a total transaction of $95,137.44.
  • On Monday, February 11th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $21.30, for a total transaction of $21,300.00.
  • On Wednesday, January 9th, Patrick J. Haley sold 1,560 shares of Exelixis stock. The shares were sold at an average price of $23.50, for a total transaction of $36,660.00.
  • On Monday, January 7th, Patrick J. Haley sold 5,560 shares of Exelixis stock. The shares were sold at an average price of $21.51, for a total transaction of $119,595.60.
  • On Wednesday, January 9th, Patrick J. Haley sold 9,120 shares of Exelixis stock. The shares were sold at an average price of $22.18, for a total transaction of $202,281.60.
  • On Thursday, January 3rd, Patrick J. Haley sold 8,000 shares of Exelixis stock. The stock was sold at an average price of $19.95, for a total transaction of $159,600.00.

Shares of Exelixis stock traded up $0.06 during trading hours on Thursday, reaching $24.77. The company’s stock had a trading volume of 214,268 shares, compared to its average volume of 3,409,492. Exelixis, Inc. has a one year low of $13.42 and a one year high of $25.27. The firm has a market capitalization of $7.42 billion, a price-to-earnings ratio of 17.31, a price-to-earnings-growth ratio of 0.77 and a beta of 2.22. The company has a current ratio of 8.50, a quick ratio of 8.41 and a debt-to-equity ratio of 0.01.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Tuesday, February 12th. The biotechnology company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.14. Exelixis had a net margin of 80.95% and a return on equity of 48.90%. The firm had revenue of $228.60 million for the quarter, compared to analyst estimates of $188.44 million. During the same period last year, the firm earned $0.12 earnings per share. The business’s quarterly revenue was up 90.4% compared to the same quarter last year. On average, research analysts forecast that Exelixis, Inc. will post 1.04 EPS for the current year.

Several research analysts recently issued reports on EXEL shares. Oppenheimer set a $40.00 target price on shares of Exelixis and gave the stock a “buy” rating in a research note on Thursday, November 15th. TheStreet raised shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, December 17th. Zacks Investment Research raised shares of Exelixis from a “strong sell” rating to a “hold” rating in a research note on Monday, March 4th. ValuEngine raised shares of Exelixis from a “sell” rating to a “hold” rating in a research note on Wednesday, January 9th. Finally, BMO Capital Markets started coverage on shares of Exelixis in a research note on Friday, February 22nd. They set a “market perform” rating and a $23.00 target price on the stock. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $29.20.

Several institutional investors have recently added to or reduced their stakes in EXEL. FTB Advisors Inc. lifted its stake in shares of Exelixis by 312.0% in the fourth quarter. FTB Advisors Inc. now owns 1,545 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,170 shares in the last quarter. JOYN Advisors Inc. lifted its stake in shares of Exelixis by 334.2% in the fourth quarter. JOYN Advisors Inc. now owns 1,524 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,173 shares in the last quarter. Cornerstone Advisors Inc. bought a new position in shares of Exelixis in the fourth quarter valued at $38,000. Financial Gravity Companies Inc. purchased a new stake in shares of Exelixis in the fourth quarter valued at about $50,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of Exelixis in the fourth quarter valued at about $59,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Exelixis, Inc. (EXEL) VP Patrick J. Haley Sells 959 Shares” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.com-unik.info/2019/03/14/exelixis-inc-exel-vp-patrick-j-haley-sells-959-shares.html.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Article: Stop Order Uses For Individual Investors

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit